Skip to main content
Erschienen in: Cancer Causes & Control 3/2015

01.03.2015 | Original paper

Blood lipids and colorectal polyps: testing an etiologic hypothesis using phenotypic measurements and Mendelian randomization

verfasst von: Michael N. Passarelli, Polly A. Newcomb, Karen W. Makar, Andrea N. Burnett-Hartman, John D. Potter, Melissa P. Upton, Lee-Ching Zhu, Michael E. Rosenfeld, Stephen M. Schwartz, Carolyn M. Rutter

Erschienen in: Cancer Causes & Control | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Studies linking cholesterol levels to the development of colorectal neoplasia are inconsistent, and Mendelian randomization has been suggested as a way to help avoid problems with confounding and reverse causation.

Methods

We genotyped individuals who received a colonoscopy at Group Health (1998–2007) for 96 of 102 single-nucleotide polymorphisms identified by the Global Lipids Genetics Consortium. Participants included 139 advanced adenoma cases, 518 non-advanced adenoma cases, 380 non-adenomatous polyp cases, and 754 polyp-free controls. All had at least one available pre-colonoscopy lipid measurement from electronic records maintained by Group Health.

Results

Advanced adenoma cases were more likely than controls to have higher pre-colonoscopy zenith low-density lipoprotein (LDL), triglycerides (TG), and total cholesterol (TC) (odds ratio, OR per 20 mg/dL LDL increase: 1.16, 95 % confidence interval, CI 1.03–1.30; per 40 mg/dL TG increase: 1.09, 1.03–1.16; and per 20 mg/dL TC increase: 1.09, 1.02–1.18). For these traits, genotype–polyp ORs using weighted allele scores were not statistically significant (OR per increase in score scaled to a 20 mg/dL LDL increase: 1.17, 0.78–1.75; a 40 mg/dL TG increase: 1.12, 0.91–1.38; a 20 mg/dL TC increase: 0.99, 0.71–1.38).

Conclusions

Cholesterol levels may be associated with advanced adenomas, but larger studies are warranted to determine whether this association can be attributed to genetics.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bayerdorffer E, Mannes GA, Richter WO et al (1993) Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Intern Med 118:481–487CrossRefPubMed Bayerdorffer E, Mannes GA, Richter WO et al (1993) Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Intern Med 118:481–487CrossRefPubMed
2.
Zurück zum Zitat Bird CL, Ingles SA, Frankl HD, Lee ER, Longnecker MP, Haile RW (1996) Serum lipids and adenomas of the left colon and rectum. Cancer Epidemiol Biomark Prev 5:607–612 Bird CL, Ingles SA, Frankl HD, Lee ER, Longnecker MP, Haile RW (1996) Serum lipids and adenomas of the left colon and rectum. Cancer Epidemiol Biomark Prev 5:607–612
3.
Zurück zum Zitat Kang HW, Kim D, Kim HJ et al (2010) Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case–control study. Am J Gastroenterol 105:178–187CrossRefPubMed Kang HW, Kim D, Kim HJ et al (2010) Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case–control study. Am J Gastroenterol 105:178–187CrossRefPubMed
4.
Zurück zum Zitat Yang MH, Rampal S, Sung J et al (2013) The association of serum lipids with colorectal adenomas. Am J Gastroenterol 108:833–841CrossRefPubMed Yang MH, Rampal S, Sung J et al (2013) The association of serum lipids with colorectal adenomas. Am J Gastroenterol 108:833–841CrossRefPubMed
5.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
6.
Zurück zum Zitat Potter JD (1999) Colorectal cancer: molecules and populations. J Natl Cancer Inst 91:916–932CrossRefPubMed Potter JD (1999) Colorectal cancer: molecules and populations. J Natl Cancer Inst 91:916–932CrossRefPubMed
7.
8.
Zurück zum Zitat Davey Smith G, Ebrahim S (2003) ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32:1–22CrossRef Davey Smith G, Ebrahim S (2003) ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32:1–22CrossRef
9.
Zurück zum Zitat Katan MB (2004) Commentary: Mendelian randomization, 18 years on. Int J Epidemiol 33:10–11CrossRefPubMed Katan MB (2004) Commentary: Mendelian randomization, 18 years on. Int J Epidemiol 33:10–11CrossRefPubMed
10.
Zurück zum Zitat Glymour MM, Tchetgen EJ, Robins JM (2012) Credible Mendelian randomization studies: approaches for evaluating the instrumental variable assumptions. Am J Epidemiol 175:332–339CrossRefPubMedCentralPubMed Glymour MM, Tchetgen EJ, Robins JM (2012) Credible Mendelian randomization studies: approaches for evaluating the instrumental variable assumptions. Am J Epidemiol 175:332–339CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Heller DA, de Faire U, Pedersen NL, Dahlen G, McClearn GE (1993) Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 328:1150–1156CrossRefPubMed Heller DA, de Faire U, Pedersen NL, Dahlen G, McClearn GE (1993) Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 328:1150–1156CrossRefPubMed
12.
13.
Zurück zum Zitat Burnett-Hartman AN, Passarelli MN, Adams SV et al (2013) Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site. Am J Epidemiol 177:625–637CrossRefPubMedCentralPubMed Burnett-Hartman AN, Passarelli MN, Adams SV et al (2013) Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site. Am J Epidemiol 177:625–637CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Burnett-Hartman AN, Newcomb PA, Hutter CM et al (2014) Variation in the association between colorectal cancer susceptibility loci and colorectal polyps by polyp type. Am J Epidemiol 180:223–232CrossRefPubMed Burnett-Hartman AN, Newcomb PA, Hutter CM et al (2014) Variation in the association between colorectal cancer susceptibility loci and colorectal polyps by polyp type. Am J Epidemiol 180:223–232CrossRefPubMed
15.
Zurück zum Zitat Winawer SJ, Zauber AG (2002) The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 12:1–9CrossRefPubMed Winawer SJ, Zauber AG (2002) The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 12:1–9CrossRefPubMed
16.
Zurück zum Zitat Saunders KW, Davis RL, Stergachis A (2000) Group Health Cooperative of Puget Sound. In: Strom BL (ed) Pharmacoepidemiology, 3rd edn. Wiley, Chichester, pp 247–262CrossRef Saunders KW, Davis RL, Stergachis A (2000) Group Health Cooperative of Puget Sound. In: Strom BL (ed) Pharmacoepidemiology, 3rd edn. Wiley, Chichester, pp 247–262CrossRef
17.
Zurück zum Zitat Burgess S (2013) Identifying the odds ratio estimated by a two-stage instrumental variable analysis with a logistic regression model. Stat Med 32:4726–4747CrossRefPubMedCentralPubMed Burgess S (2013) Identifying the odds ratio estimated by a two-stage instrumental variable analysis with a logistic regression model. Stat Med 32:4726–4747CrossRefPubMedCentralPubMed
18.
19.
Zurück zum Zitat Thompson SG, Higgins J (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573CrossRefPubMed Thompson SG, Higgins J (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573CrossRefPubMed
20.
Zurück zum Zitat Cholesterol Treatment Trialists’ Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681CrossRef Cholesterol Treatment Trialists’ Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681CrossRef
21.
Zurück zum Zitat Cai B, Small DS, Have TR (2011) Two-stage instrumental variable methods for estimating the causal odds ratio: analysis of bias. Stat Med 30:1809–1824CrossRefPubMed Cai B, Small DS, Have TR (2011) Two-stage instrumental variable methods for estimating the causal odds ratio: analysis of bias. Stat Med 30:1809–1824CrossRefPubMed
22.
Zurück zum Zitat VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P (2014) Methodological challenges in Mendelian randomization. Epidemiology 25:427–435CrossRefPubMed VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P (2014) Methodological challenges in Mendelian randomization. Epidemiology 25:427–435CrossRefPubMed
23.
Zurück zum Zitat Pierce BL, Ahsan H, Vanderweele TJ (2011) Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 40:740–752CrossRefPubMedCentralPubMed Pierce BL, Ahsan H, Vanderweele TJ (2011) Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 40:740–752CrossRefPubMedCentralPubMed
24.
25.
Zurück zum Zitat Jiao S, Peters U, Berndt S et al (2014) Estimating the heritability of colorectal cancer. Hum Mol Genet 23:3898–3905CrossRefPubMed Jiao S, Peters U, Berndt S et al (2014) Estimating the heritability of colorectal cancer. Hum Mol Genet 23:3898–3905CrossRefPubMed
26.
Zurück zum Zitat Wang J, Carvajal-Carmona LG, Chu JH et al (2013) Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res 19:6430–6437CrossRefPubMedCentralPubMed Wang J, Carvajal-Carmona LG, Chu JH et al (2013) Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res 19:6430–6437CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Edwards TL, Shrubsole MJ, Cai Q et al (2013) Genome-wide association study identifies possible genetic risk factors for colorectal adenomas. Cancer Epidemiol Biomark Prev 22:1219–1226CrossRef Edwards TL, Shrubsole MJ, Cai Q et al (2013) Genome-wide association study identifies possible genetic risk factors for colorectal adenomas. Cancer Epidemiol Biomark Prev 22:1219–1226CrossRef
28.
Zurück zum Zitat Tenesa A, Dunlop MG (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10:353–358CrossRefPubMed Tenesa A, Dunlop MG (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10:353–358CrossRefPubMed
29.
Zurück zum Zitat Peters U, Jiao S, Schumacher FR et al (2013) Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology 144:799–807CrossRefPubMedCentralPubMed Peters U, Jiao S, Schumacher FR et al (2013) Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology 144:799–807CrossRefPubMedCentralPubMed
30.
Zurück zum Zitat Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG (2005) Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol Biomark Prev 14:1545–1551CrossRef Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG (2005) Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol Biomark Prev 14:1545–1551CrossRef
Metadaten
Titel
Blood lipids and colorectal polyps: testing an etiologic hypothesis using phenotypic measurements and Mendelian randomization
verfasst von
Michael N. Passarelli
Polly A. Newcomb
Karen W. Makar
Andrea N. Burnett-Hartman
John D. Potter
Melissa P. Upton
Lee-Ching Zhu
Michael E. Rosenfeld
Stephen M. Schwartz
Carolyn M. Rutter
Publikationsdatum
01.03.2015
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 3/2015
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-015-0526-3

Weitere Artikel der Ausgabe 3/2015

Cancer Causes & Control 3/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.